Table 2 Baseline characteristics of patients stratified by type‐D personality.
| Total sample | Type‐D personality (n = 42) | Non‐type‐D personality (n = 136) | p Value | |
|---|---|---|---|---|
| Mean (SD) age, years | 66.6 (8.4) | 68.2 (7.8) | 66.1 (8.6) | 0.16 |
| Men, n (%) | 140 (79) | 33 (79) | 107 (79) | 0.98 |
| Lower educational level, n (%) | 154 (87) | 39 (93) | 115 (85) | 0.17 |
| Having no partner, n (%) | 43 (24) | 12 (29) | 31 (23) | 0.45 |
| Mean (SD) LVEF% | 29.9 (6.7) | 28.9 (6.6) | 30.2 (6.7) | 0.32 |
| NYHA class III and IV, n (%) | 96 (54) | 28 (67) | 68 (50) | 0.06 |
| Ischaemic aetiology, n (%) | 101 (56) | 24 (57) | 76 (56) | 0.86 |
| Mean (SD) time since diagnosis | 3.9 (4.1) | 3.4 (4.1) | 4.0 (4.1) | 0.34 |
| ACE‐inhibitor users, n (%) | 142 (80) | 33 (79) | 109 (80) | 0.82 |
| All‐antagonist users, n (%) | 30 (17) | 8 (19) | 22 (16) | 0.66 |
| Diuretic users, n (%) | 142 (80) | 39 (93) | 103 (76) | 0.02* |
| Digitalis users, n (%) | 56 (32) | 15 (36) | 41 (30) | 0.50 |
| β‐Blocker users, n (%) | 116 (65) | 31 (74) | 85 (63) | 0.18 |
| Long‐acting nitrate users, n (%) | 44 (25) | 14 (33) | 30 (22) | 0.14 |
| Short‐acting nitrate users, n (%) | 17 (10) | 7 (17) | 10 (7) | 0.07 |
| Calcium antagonist users, n (%) | 16 (9) | 8 (19) | 8 (6) | 0.01* |
| Anticoagulant users, n (%) | 77 (43) | 17 (41) | 60 (44) | 0.68 |
| Aspirin users, n (%) | 80 (45) | 19 (45) | 61 (45) | 0.97 |
| Statin users, n (%) | 84 (47) | 20 (48) | 64 (47) | 0.95 |
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
*p<0.05.